Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Synopsys, Inc. (SNPS) vs Teladoc Health Inc (TDOC) Price & Performance

Synopsys, Inc.Trade
Teladoc Health IncTrade

Price performance (Past 24H)

Key statistics

Synopsys, Inc. vs Teladoc Health Inc — how do they compare? Synopsys, Inc. trades at $414.36 (market cap $78.68B), while Teladoc Health Inc trades at $6.64 (market cap $1.24B). The key difference: Synopsys, Inc. is far larger — about 63.5× Teladoc Health Inc's market cap, and Teladoc Health Inc is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.

SNPSTDOC
Market Cap
$78.68B$1.24B
Sector
TechnologyHealth
52-Week High
$625.80$9.72
52-Week Low
$372.33$4.47
Enterprise Value
$87.04B$1.50B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Synopsys, Inc.

Synopsys (SNPS) trades at $411.68, down 1.04% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish overall signal despite recent volatility, with strong analyst support (82.76% buy ratings) and a consensus price target of $551.00. Recent earnings beats and strategic moves like the Ansys acquisition highlight robust growth prospects in the semiconductor design software space, though high valuation multiples and significant cash flow volatility warrant caution.

The outlook for SNPS remains positive driven by AI-driven demand and recurring revenue streams, but investors face risks from elevated valuations, integration challenges from acquisitions, and semiconductor cycle sensitivity. The stock's current price near key support levels offers a potential entry point for long-term growth investors, contingent on sustained execution and market conditions.

Teladoc Health Inc

Teladoc Health (TDOC) trades at $7.08, down 0.7% for the day, with a bearish technical signal and negative earnings. The stock faces pressure from a recent 28% drop after Q2 2026 revenue missed estimates and full-year guidance was cut. Valuation metrics like P/S of 0.49 and EV/EBITDA of 6.96 appear low, but profitability remains weak with a -7.13% net income margin. Multiple law firms are investigating potential securities violations, adding to investor concerns.

The outlook is cautious due to ongoing losses and competitive pressures in virtual care. Risks include execution challenges at the BetterHelp unit and regulatory scrutiny. Analyst consensus is mixed with a $8.88 price target, but near-term volatility is likely amid negative sentiment and fundamental headwinds.

Returns comparison

Trailing returns across standard periods

About Synopsys, Inc.

Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.

Read more on SNPS

About Teladoc Health Inc

Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.

Read more on TDOC